Featured Inquiries and Replies
Ask an Expert
GI Cancer
GI Cancer Specialist
Just a general principle question. In anal cancer metastatic to liver, I used carboplatin and paclitaxel with good responce after 6 cycles. How long can you continue these chemo? Is there a limit to number of cycles? Or role of chemo holiday? Going to one of the chemo? Or stopping after certain fixed amount of cycles?
Read Response
Breast | Age 43 | New Dx
Breast Cancer Specialist
I have a 43 year old premenopausal woman with de novo Stage 4 Triple Positive Breast Cancer (ER/PR 70%, HER 2 3+) with brain and lung mets. Got SBRT to brain for lesions. Now starting docetaxel plus dual her2. What is your approach to endocrine therapy and ovarian suppression in this setting?
Read Response
Lung | Age 80
Lung Cancer Specialist
80yr female, ECOG 0 with stage IV EGFR exon 21 L 858R lung adeno, PDL1 5%. Just completed palliative RT for painful right chest wall lesion. Would you use osimertinib alone or with carbo/Pem?
Read Response
H&N | Age 58 | R/R
Head and Neck Cancer Specialist
58 year old female with SCC of supraglottic larynx, initially diagnosed as T2N0M0 received RT, total laryngectomy, then concurrent cisplatin+RT on local recurrence. Patient then progressed so started pembro but patient is experiencing clinical and radiographic progression. Is cetuximab my next best option?
Read Response
GI Cancer | Age 43
GI Cancer Specialist
43 M with Cirrhosis and a newly diagnosed rectal adenocarcinoma. Rectal cancer is locally advanced. He was evaluted by surgical team and mass was thought to be unresectable. Planned for total neoadjuvant therapy with 5FU continuous chemoradiation. For TNT, does the sequence matter?
Read Response
Breast Cancer | Age 71 | New Dx
Breast Cancer Specialist
71 year old female with cT1 cN0 cM0 IDC of the right breast, grade 2, ER 5%, PR negative, HER2 negative, Ki 67 24% being referred to medical oncology. MammaPrint and BluePrint results: Basal-type, high risk 1 (index -0.324), probability of pCR 34%. Would you offer neoadjuvant chemotherapy given the low ER expression and high risk genomic score that would warrant chemo anyway?
Read Response
Ask an Expert
Disclaimer: These are examples of platform discussions and should be viewed for educational purposes only.